09/08/23 7:00 AMNasdaq : BCTX, BCTXW low floatBriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast CancerMedian overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen NoRHEA-AIvery positive
08/31/23 11:54 AMNasdaq : BCTX, BCTXW low floatBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell" or the " Company"), a clinical-stage biotechnology company thatRHEA-AInegative
08/31/23 8:21 AMNasdaq : BCTX, BCTXW clinical triallow floatBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it hasRHEA-AIneutral
08/25/23 2:33 PMNasdaq : BCTX, BCTXW low floatBriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing ShareholdersBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stageRHEA-AIneutral
08/18/23 12:21 PMNasdaq : BCTX, BCTXW low floatBriaCell Therapeutics Corp. Announces Voting Results From Special MeetingShareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx and and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer Share reorganization expected to take place immediately prior toRHEA-AIneutral
08/16/23 8:36 AMNasdaq : BCTX, BCTXW low floatBriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for CancerBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)RHEA-AIpositive
07/07/23 8:10 AMNasdaq : IPA, BCTX, BCTXW earningsImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023IPA, an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023.. In the fiscal year ended April 30, 2023, we achieved a revenue of $20.7 million, marking a notable 6.7% increase compared to the year ended April 30, 2022. We also recorded our highest quarterly revenue total...RHEA-AIpositive
06/27/23 8:05 AMNasdaq : BCTX, BCTXW fda approvallow floatFDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has receivedRHEA-AIpositive
05/25/23 9:00 AMNasdaq : BCTX, BCTXW low floatBriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology company specializing in targetedRHEA-AIneutral
05/19/23 11:38 AMNasdaq : BCTX, BCTXW low floatBriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per ShareBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that theRHEA-AIneutral
